Riskpilot← Back to searchSign inGet full accessBioAll AB
ABActiveOrg 5569652141Vårbacken 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20141 employees
Revenue 2024
SEK 0
EBITDA margin
—
-12% vs 2023
Equity ratio
95.7%
Financial strength
Net profit 2024
SEK 1,2M
+176% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | -12% |
| Net profit | SEK 1,2M | +176% |
| Total assets | SEK 2,7M | +150% |
| Equity | SEK 2,6M | +172% |
| Employees | 1 | — |
Legal name
BioAll AB
Org number
5569652141
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 mars 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva köp, försäljning och förvaltning av värdepapper samt konsultverksamhet inom bioteknologi, medicin samt företagsledning och marknadsföring och därmed förenlig verksamhet
Address
Vårbacken 3
Email
mathias.svahn@me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7 | 0 | 0 |
| Staff expenses | — | — | — | −1 | −0 |
| EBITDA | −53 | −20 | −16 | −16 | −18 |
| Depreciation & amort. | −1 | −1 | −1 | — | — |
| EBIT | −54 | −21 | −17 | −16 | −18 |
| Net financials | −233 | −396 | −301 | −1 736 | 1 239 |
| Profit before tax | 539 | −30 | −308 | −1 598 | 1 236 |
| Tax | −34 | −36 | — | −22 | — |
| Net profit | 505 | −66 | −308 | −1 620 | 1 236 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 353 | 3 073 | 2 752 | 1 097 | 2 738 |
| Equity | 2 247 | 2 181 | 1 873 | 965 | 2 621 |
| Long-term debt | 400 | 400 | 400 | 0 | — |
| Short-term debt | 237 | 223 | 219 | 26 | 25 |
| Total debt | 637 | 623 | 619 | 26 | 25 |
EBITDA margin
-1774600.0%
This company
15.8%
Market median
-11231746% vs market
20202024
Equity ratio
95.7%
This company
38.2%
Market median
+151% vs market
20202024
Return on equity
47.1%
This company
18.4%
Market median
+156% vs market
20202024
Net profit margin
123593800.0%
This company
8.1%
Market median
+1525849283% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioAll AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Katarina Rasch Svahn | Deputy Board Member | 0 companies |
| Mathias Gösta Svahn | Board of Directors | 0 companies |